4-(1-oxido-3-pyridinyl)benzoic acid | 328125-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(1-oxido-3-pyridinyl)benzoic acid
• 英文别名: 4-(3-pyridyl)benzoic acid N-oxide；4-(1-Oxypyridin-3-yl)benzoic acid；4-[pyridine-N-oxide-3-yl]-Benzoic Acid；4-(1-oxidopyridin-1-ium-3-yl)benzoic acid
• CAS: 328125-43-5
• 化学式: C₁₂H₉NO₃
• 分子量: 215.208
• InChiKey: UQTIMPXCTPPTSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  523.8±43.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1-oxido-3-pyridinyl)benzoic acid 、 copper(II) nitrate trihydrate 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以58%的产率得到poly[Cu(4-(3-pyridyl)benzoic acid N-oxide(-H))(OH)]
  参考文献：
  名称：

  衍生自苯甲酸吡啶酯N-氧化物配体的混合羟基羧酸盐桥的两种铜（II）化合物的结构和磁性

  摘要：

  摘要两种具有两个异构的吡啶基苯甲酸N-氧化物配体的Cu（II）配位聚合物，4-（4-吡啶基）苯甲酸N-氧化物（4,4-Hopybz）或4-（3-吡啶基）苯甲酸N-氧化物（合成了4,3-Hopybz），并在结构和磁学上进行了表征。它们被公式化为[Cu（4,4-opybz）（OH）] n（1）和[Cu（4,3-opybz）（OH）] n（2）。两种化合物显示出相似的层结构，其中具有均匀[[μ-OH]（μ-COO）]双桥的1D配位链通过4,4-opybz或4,3-opybz配体连接。磁性研究表明，混合双桥在化合物1中传递铁磁耦合，在化合物2中存在反铁磁相互作用。磁性差异可能与受吡啶基苯甲酸酯N-氧化物配体影响的Cu-O-Cu角有关。

  DOI：

  10.1016/j.ica.2015.10.022
• 作为产物：
  描述：

  4-吡啶-3-基-苯甲酸 以 间氯过氧苯甲酸 为溶剂， 以86%的产率得到4-(1-oxido-3-pyridinyl)benzoic acid
  参考文献：
  名称：

  Pharmaceutically active pyrrolidine derivatives

  摘要：

  本发明涉及式(I)的吡咯烷衍生物。所述化合物优选用作药用活性化合物。具体而言，式(I)的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示出氧催产素受体显著调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地，所述化合物在治疗和/或预防由氧催产素介导的疾病状态，包括早产、早产和痛经方面是有用的。本发明还涉及新型吡咯烷衍生物以及其制备方法，其中X从CR6R7、NOR6、NNR6R7组中选择；A从—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO22—、—SO2NH—、—CH2—中选择；B是一个群—(C═O)—NR8R9或表示具有式(a)的杂环残基，其中Q是NR10、O或S；n是选择的整数0、1或2；Y、Z和E与它们连接的2个碳一起形成一个5-6成员芳基或杂芳基环。

  公开号：

  US20030212012A1

文献信息

• Pharmaceutically active pyrrolidine derivatives as bax inhibitors
  申请人：——

  公开号：US20030171309A1

  公开（公告）日：2003-09-11

  The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CR<6>R<7>, NOR<6>, NNR<6>R<7>; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2-, —SO2NH—; —CH2-; B is either a group —(C═O)—NR<8>R<9> or represents a heterocyclic residue having the formula (II) wherein Q is NR<10>, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及新的取代吡咯烷衍生物的化学式(I)。所述化合物通常用作药用活性化合物。具体来说，化学式(I)的吡咯烷衍生物在治疗和/或预防神经退行性疾病、与多谷氨酸氨基酸序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病方面具有用处。所述吡咯烷衍生物显示出对细胞死亡促进子Bax和/或导致Bax激活途径的调节作用，最显著地是下调至抑制活性，并因此允许阻止细胞色素(c)的释放。本发明还涉及新的具有药用活性的取代吡咯烷衍生物，以及它们的制备方法，其中X选自O、S、CR<6>R<7>、NOR<6>、NNR<6>R<7>组成的群；A选自—(C═O)—、—(C═O)—O—、—C(═NH)—、—(C═O)—NH—、—(C═S)—NH、—SO2-、—SO2NH—；—CH2-；B是一个群—(C═O)—NR<8>R<9>或代表具有化学式(II)的杂环残基，其中Q是NR<10>、O或S；n是选自0、1或2的整数；Y、Z和E与它们连接的两个碳共同形成一个5-6成员芳香族或杂芳族环。
• Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
  申请人：——

  公开号：US20020193410A1

  公开（公告）日：2002-12-19

  This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).

  这项发明涉及取代的（氨基亚甲基或氨甲基）二氢苯并呋喃和苯并吡喃，这些化合物抑制因子Xa，包括这些化合物的药物组合物以及它们用于抑制因子Xa或治疗可以通过给予这些化合物改善的患者的病理状况。这项发明还涉及取代的（氨基亚甲基或氨甲基）二氢苯并呋喃和苯并吡喃，直接抑制因子Xa和因子IIa（凝血酶），包括这些化合物的药物组合物，用于制备这些化合物的中间体，以及同时直接抑制因子Xa和因子IIa（凝血酶）的方法。
• Structural diversity of Mn(<scp>ii</scp>), Zn(<scp>ii</scp>) and Pb(<scp>ii</scp>) coordination polymers constructed from isomeric pyridylbenzoate N-oxide ligands: structures and electrochemical properties
  作者：Lei Hu、Xiao-Ming Lin、Jia Lin、Ru-Qiao Zhang、Da-Liang Zhang、Yue-Peng Cai

  DOI：10.1039/c6ce02071b

  日期：——

  Several new coordination polymers (CPs), [Mn(4,3-opybz)2(H2O)2]n (1), [Zn(4,3-opybz)(OH)]n (2), [Pb(4,3-opybz)(H2O)]·(NO3)}n (3), [Mn3(4,4-opybz)4(HCOO)2(H2O)4]·6H2O}n (4), Zn(4,4-opybz)2(H2O)2 (5) and [Pb(4,4-opybz)(4,3-opybz)]·3DMF·7H2O}n (6) (4,4-Hopybz = 4-(4-pyridyl)benzoic acid N-oxide, 4,3-Hopybz = 4-(3-pyridyl)benzoic acid N-oxide), have been successfully synthesized and characterized by

  几种新的配位聚合物（CP），[Mn（4,3-opybz）2（H 2 O）2 ] n（1），[Zn（4,3-opybz）（OH）] n（2），[ Pb（4,3-opybz）（H 2 O）]·（NO 3）} n（3），[Mn 3（4,4-opybz）4（HCOO）2（H 2 O）4 ]·6H 2 O} n（4），Zn（4,4-opybz）2（H 2 O）2（5）和[Pb（4,4-opybz）（4,3-opybz）]·3DMF·7H2 O} n（ 6）（4,4-Hopybz = 4-（4-吡啶基）苯甲酸N-氧化物，4,3-Hopybz = 4-（3-吡啶基）苯甲酸N-氧化物）已成功通过元素分析，红外光谱，热重分析和单晶X射线衍射合成和表征。结构分析表明，复合物1具有带有6 3拓扑的二维（2D）层。复合体2和3提供了具有4·8 2拓扑的2D层体系结构。复杂物4提供了一个由线性三核二级建筑单元
• [EN] PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS<br/>[FR] DERIVES DE LA PYRROLIDINE PHARMACEUTIQUEMENT ACTIFS COMME INHIBITEURS DE BAX
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2001074769A1

  公开（公告）日：2001-10-11

  The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating - up to an inhibitory - activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CR?6R7, NOR6, NNR6R7¿; A is selected from the group consisting of -(C=O)-, -(C=O)-O-, -C(=NH)-, -(C=O)-NH-, -(C=S)-NH, -SO¿2?-, -SO2NH-; -CH2-; B is either a group -(C=O)-NR?8R9¿ or represents a heterocyclic residue having the formula (II) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及公式（I）的新取代吡咯烷衍生物。所述化合物优选用作药物活性化合物。具体而言，公式（I）的吡咯烷衍生物在神经退行性疾病、与多谷氨酸重复序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病的治疗和/或预防中有用。所述吡咯烷衍生物显示出调节性，尤其是对于细胞死亡促进剂Bax和/或导致Bax的激活途径具有下调至抑制性的活性，并因此允许阻止细胞色素（c）的释放。本发明还涉及新型药物活性取代吡咯烷衍生物以及其制备方法，其中X选自O，S，CR?6R7，NOR6，NNR6R7¿的群；A选自-(C=O)-，-(C=O)-O-，-C（=NH）-，-(C=O)-NH-，-(C=S)-NH，-SO¿2?，-SO2NH-；-CH2-；B是一个-(C=O)-NR?8R9¿基团或代表具有公式（II）的杂环残基，其中Q是NR10，O或S；n是选择的0、1或2的整数；Y、Z和E与它们所连接的2个碳一起形成一个5-6成员芳基或杂芳基环。
• [EN] PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS<br/>[FR] DERIVES PYRROLIDINE ACTIFS SUR LE PLAN PHARMACEUTIQUE UTILISES EN TANT QU'INHIBITEURS DE BAX
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2001072705A1

  公开（公告）日：2001-10-04

  The present invention is related to pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR?6R7, NOR6, NNR6R7¿; A is selected from the group consisting of -(C=O)-, -(C=O)-O-, -C(=NH)-, -(C=O)-NH-, -(C=S)-NH, -SO¿2?2-, -SO2NH-, -CH2-,B is either a group -(C=O)-NR?8R9¿ or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

  本发明涉及式（I）的吡咯烷衍生物。所述化合物最好用作药物活性化合物。具体而言，式（I）的吡咯烷衍生物在治疗和/或预防早产、早产和痛经方面是有用的。特别是，本发明涉及显示氧合胃素受体重要调节作用，特别是拮抗剂活性的吡咯烷衍生物。更具体地说，所述化合物在治疗和/或预防由氧合胃素介导的疾病状态方面是有用的，包括早产、早产和痛经。本发明还涉及新的吡咯烷衍生物以及其制备方法，其中X选自CR？6R7，NOR6，NNR6R7¿组成的群；A选自-(C=O)-，-(C=O)-O-，-C（=NH）-，-(C=O)-NH-，-(C=S)-NH，-SO¿2？2-，-SO2NH-，-CH2-；B是-(C=O)-NR？8R9¿或表示具有公式（a）的杂环残基，其中Q是NR10，O或S；n是选择的整数0、1或2；Y、Z和E与它们附着的2个碳原子一起形成一个5-6成员芳香族或杂芳基环。